연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
1365. Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer.
Keam B1, Im SA, Lim Y, Han SW, Moon HG, Oh DY, Cho N, Lee SH, Han W, Moon WK, Kim DW, Kim TY, Park IA, Noh DY.
Ann Surg Oncol. 2013 Jul;20(7):2242-9. doi: 10.1245/s10434-012-2756-x. Epub 2013 Mar 26.
Link
1364. Clinical outcomes of radiation-based locoregional therapy in locally advanced head and neck squamous cell carcinoma patients not responding to induction chemotherapy.
Lim Y1, Keam B, Koh Y, Kim TM, Lee SH, Hah JH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS, Kim KH.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Jul;116(1):55-60. doi: 10.1016/j.oooo.2013.02.007. Epub 2013 Apr 6.
Link
1363. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.
Lee E1, Keam B, Kim DW, Kim TM, Lee SH, Chung DH, Heo DS.
J Thorac Oncol. 2013 Aug;8(8):1069-74. doi: 10.1097/JTO.0b013e318294c8e8.
Link
1362. Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer.
Keam B1, Kim DW, Park JH, Lee JO, Kim TM, Lee SH, Chung DH, Heo DS.
Int J Clin Oncol. 2013 Aug 6. [Epub ahead of print]
Link
1361. How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution.
Keam B1, Kim DW, Park JH, Lee JO, Kim TM, Lee SH, Chung DH, Heo DS.
Cancer Res Treat. 2013 Sep;45(3):178-85. doi: 10.4143/crt.2013.45.3.178. Epub 2013 Sep 30.
Link
1360. Clinical significance of downstaging in patients with limited-disease small-cell lung cancer.
Go SI1, Keam B2, Kim TM3, Lee SH3, Kim DW3, Kim HJ4, Wu HG4, Chung DH5, Heo DS3.
Clin Lung Cancer. 2014 Mar;15(2):e1-6. doi: 10.1016/j.cllc.2013.09.003. Epub 2013 Nov 14.
Link
1359. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT.
Choi H1, Paeng JC, Kim DW, Lee JK, Park CM, Kang KW, Chung JK, Lee DS.
Lung Cancer. 2013 Mar;79(3):242-7. doi: 10.1016/j.lungcan.2012.11.021. Epub 2012 Dec 20.
Link
1358. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer.
Lira ME1, Kim TM, Huang D, Deng S, Koh Y, Jang B, Go H, Lee SH, Chung DH, Kim WH, Schoenmakers EF, Choi YL, Park K, Ahn JS, Sun JM, Ahn MJ, Kim DW, Mao M.
J Mol Diagn. 2013 Jan;15(1):51-61. doi: 10.1016/j.jmoldx.2012.08.006. Epub 2012 Dec 12.
Link
1357. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
Kim S1, Kim TM, Kim DW, Go H, Keam B, Lee SH, Ku JL, Chung DH, Heo DS.
J Thorac Oncol. 2013 Apr;8(4):415-22. doi: 10.1097/JTO.0b013e318283dcc0.
Link
1356. Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer.
Keam B1, Kim DW, Park JH, Lee JO, Kim TM, Lee SH, Chung DH, Heo DS.
Int J Clin Oncol. 2013 Aug 6. [Epub ahead of print]
Link